Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Status:
Completed
Trial end date:
2021-01-08
Target enrollment:
Participant gender:
Summary
Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2
(COVID-19) associated with organ dysfunction and with laboratory findings of macrophage
activation syndrome or immune dysregulation. These patients will be selected by the use of a
panel of biomarkers and laboratory findings and they will be allocated to immunotherapy
treatment according to their needs.